Lakefront Biotherapeutics NV (LKFT) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · United States · ISIN US36315X1019

Price
28.23 USD
Market cap
1.86 bn USD
P/E (2025)
5.80
P/S (2025)
1.67
Dividend yield
0.00 %
Net margin
28.85 %
Return on equity (ROE)
9.92 %
Return on assets (ROA)
9.42 %

Lakefront Biotherapeutics NV financials

Fiscal year20242025
Revenue275.65 m EUR1.11 bn EUR
Gross profit240.79 m EUR1.08 bn EUR
Operating income-188.34 m EUR501.39 m EUR
EBIT-2.17 m EUR303.09 m EUR
Net income74.08 m EUR320.88 m EUR
Diluted EPS – continuing operations1.12 EUR4.87 EUR

Full history since 2021, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Lakefront Biotherapeutics NV

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 26.10.2026. Details in the risk notice.